Phase 2 (Data)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Neratinib for Bile duct cancer patients with HER2 mutations
ClinicalTrials.gov (NCT01953926): Neratinib HER Mutation Basket Study (SUMMIT)
WHAT IS THE CATALYST EVENT?
Phase 2 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
H1 2021 (see slide 51)
2019: O-005 Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’trial. Annals of Oncology, 30(Supplement_4), mdz154-004.
MECHANISM OF ACTION
Neratinib is an intracellular kinase inhibitor that irreversibly binds to epidermal growth factor receptor (EGFR), HER2, and HER4. In vitro, neratinib reduces EGFR and HER2 autophosphorylation, downstream MAPK and AKT signaling pathways, and showed antitumor activity in EGFR and/or HER2 expressing carcinoma cell lines. Neratinib human metabolites M3, M6, M7 and M11 inhibited the activity of EGFR, HER2, and HER4 in vitro. In vivo, oral administration of neratinib inhibited tumor growth in mouse xenograft models with tumor cell lines expressing HER2 and EGFR.
About 8,000 people in the United States are diagnosed with it each year.
Learn more at Cancer.org
Updated by HC
cholangiocarcinoma, bile duct cancer, Neratinib, PBYI
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post